Immix Biopharma Subsidiary Nexcella Completes Pre-IND Meetin

LOS ANGELES, June 26, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering cell therapies target...

Related Keywords

Los Angeles , Alex Lobo , Ilya Rachman , Gabriel Morris , International Myeloma Working Group , Immix Biopharma Inc , Company Contact , Exchange Commission , Nexcella Inc , Immix Biopharma , Pre Investigational New Drug , Chief Executive Officer , Chief Financial Officer , Multiple Myeloma , Uniform Response Criteria , Tissue Specific Therapeutics , Orphan Drug Designation , Rare Pediatric Disease Designation , Risk Factor , Annual Report ,